FDA authorizes Merck’s anti-coronavirus pill, a second treatment option
Molnupiravir cut the risk of hospitalization and death in high-risk patients by 30%. In contrast, Pfizer’s antiviral drug, authorized on Wednesday, reduced hospitalizations and death by nearly 90%.